October 22 & 23, 2020
Institut Pasteur
6th edition

Organized by

Arun Sanyal
Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA

Lawrence Serfaty
Hôpital Hautepierre Hôpitaux Universitaires de Strasbourg, France

Scientific committee

Quentin Anstee
Pierre Bedossa
Laurent Castera
Jean-François Dufour
Scott Friedman
Fabio Marra
Philippe Mathurin
Veronica Miller
Manuel Romero-Gómez
Frank Tacke
Michael Trauner
THURSDAY, OCTOBER 22, 2020

08:00 - 08:30 am  CONFERENCE OPENING
08:30 - 08:35 am  Welcome remarks - Lawrence Serfaty (France)
08:35 - 08:45 am  Inauguration Address - Director Pasteur Institute

08:45 - 10:00 am  SESSION 1 • PUBLIC HEALTH AND POLICY
Chairs: Patrick Marcellin (France) and Arun Sanyal (USA)

08:45 - 09:00 am  A patient's journey with NASH.
Eu patient

09:00 - 09:15 am  Primary care referral for NAFLD: the UK experience.
Emmanuel Tsochatzis (United Kingdom)

09:15 - 09:30 am  Generating real world evidence from efficacy to effectiveness.
Michael Fried (USA)

09:30 - 10:00 am  Discussion

10:00 - 10:30 am  COFFEE BREAK AND POSTERS

10:30 - 12:00 am  SESSION 2 • GENETIC AND METABOLIC DRIVERS OF DISEASE PROGRESSION
Chairs: Philippe Mathurin (France) and Lawrence Serfaty (France)

10:30 - 10:45 am  Gene-environment interactions in NASH.
Stefano Romeo (Sweden)

10:45 - 11:00 am  Metabolic flexibility is the key to the biology of NASH.
Mohammad Siddiqui (USA)

11:00 - 11:15 am  What can we learn from lipodystrophies about NASH.
Jocelyne Magré (France)

11:15 - 11:30 am  Pharmacogenomic of NASH

11:30 - 12:00 pm  Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:00 - 12:30 pm | **STATE OF THE ART LECTURE**  
Chair: Arun Sanyal (USA)  
Bile acid-Microbiome interactions in the development of human disease.  
TBC                     |
| 12:30 - 02:30 pm | **LUNCH BREAKOUT SESSION - CASE BASED DISCUSSIONS**  
GROUP 1: Industry symposium  
GROUP 2: How to integrate NASH assessment and management into the care of the patient with metabolic syndrome.  
Laurent Castera (France) and Mary Rinella (USA)  
GROUP 3: Management of obesity by targeting gut hormones  
Luc Van Gaal (Belgium) and Bart Staels (France)               |
| 02:30 - 04:00 pm | **SESSION 3 • CLINICAL ASPECTS OF NAFLD**  
Chairs: Fabio Marra (Italy) and Lawrence Serfaty (France)  
02:30 - 02:45 pm | Does NASH contribute to clinical course of patients after successful HCV therapy  
Lawrence Serfaty (France)                   |
| 02:45 - 03:00 pm | Gender difference in NASH susceptibility  
Philippe Mathurin (France)                  |
| 03:00 - 03:15 pm | When disease activity can be confused with DILI in the patient  
Arie Regev (USA)                          |
| 03:15 - 03:30 pm | Modeling the risk of HCC in NAFLD  
Jean-François Dufour (Switzerland)            |
| 03:30 - 04:00 pm | Discussion                                                             |
| 04:00 - 04:30 pm | **COFFEE BREAK AND POSTERS**                                         |
### SESSION 4 • TECHNOLOGICAL INNOVATIONS IN NASH
Chairs: Manuel Romero-Gómez (Spain) and Franck Tacke (Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>04:30 - 04:45 pm</td>
<td>Progress in histological assessment of NASH: new classifications, digital imaging, machine learning.</td>
<td>Pierre Bedossa (France)</td>
</tr>
<tr>
<td>04:45 - 05:00 pm</td>
<td>Can iPSC derived from circulating cells be used to obtain insights on liver disease status?</td>
<td>Bani Mukhopadhyay (USA)</td>
</tr>
<tr>
<td>05:00 - 05:15 pm</td>
<td>What can we learn from cardiopoietic therapy approaches to resolve cirrhosis?</td>
<td>Scott Friedman (USA)</td>
</tr>
<tr>
<td>05:15 - 05:30 pm</td>
<td>Application of single cell seq in understanding NASH and liver fibrosis.</td>
<td>Thomas Baumert (France)</td>
</tr>
<tr>
<td>05:30 - 06:00 pm</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### FRIDAY, OCTOBER 23, 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:45 - 08:00 am</td>
<td>WELCOME DESK OPENING</td>
</tr>
</tbody>
</table>

### SESSION 5 • INNOVATIONS IN TRIAL DESIGN AND OUTCOMES ASSESSMENT
Chairs: Laurent Castera (France) and Jean-François Dufour (Switzerland)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:15 am</td>
<td>Assessment of causality in suspected DILI.</td>
<td>Alexander Gerbes (Germany)</td>
</tr>
<tr>
<td>08:15 - 08:30 am</td>
<td>Innovations in imaging to assess metabolic stress, inflammation and function of the liver.</td>
<td>Lars Johansson (Sweden)</td>
</tr>
<tr>
<td>08:30 - 08:45 am</td>
<td>Hierarchical endpoints for NASH.</td>
<td>Dianne Finkelstein, (USA)</td>
</tr>
<tr>
<td>08:45 - 09:15 am</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:15 - 09:45 am</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>09:45 - 11:30 am</td>
<td><strong>SESSION 6 • ADVANCES IN NASH PHARMACOLOGY</strong></td>
</tr>
<tr>
<td>09:45 - 10:00 am</td>
<td>The FGF axis in NASH. Comparison of FGF21 and FGF19 analogs.</td>
</tr>
<tr>
<td>10:00 - 10:15 am</td>
<td>The impact of SGLT2 inhibition on metabolic homeostasis.</td>
</tr>
<tr>
<td>10:15 - 10:30 am</td>
<td>Small molecule therapy.</td>
</tr>
<tr>
<td>11:00 - 11:30 am</td>
<td>Debate: The best approach to NASH is to treat the root cause rather than a pure anti-fibrotic strategy.</td>
</tr>
<tr>
<td>11:00 - 11:30 am</td>
<td>For: Philip Newsome (United Kingdom)</td>
</tr>
<tr>
<td>11:00 - 11:30 am</td>
<td>Against: Fabio Marra (Italy)</td>
</tr>
<tr>
<td>11:30 - 12:00 pm</td>
<td><strong>SPECIAL LECTURE</strong></td>
</tr>
<tr>
<td></td>
<td>Redefining the metabolic syndrome as a systemic steatosis-inflammation-fibrosis syndrome</td>
</tr>
<tr>
<td>12:00 - 02:00 pm</td>
<td><strong>LUNCH BREAKOUT SESSION</strong></td>
</tr>
<tr>
<td></td>
<td><strong>GROUP 1:</strong> Industry symposium</td>
</tr>
<tr>
<td></td>
<td><strong>GROUP 2:</strong> Review of recent clinical trials of NASH.</td>
</tr>
<tr>
<td></td>
<td><strong>GROUP 3:</strong> Endoscopic bariatric and metabolic therapies.</td>
</tr>
<tr>
<td>02:00 - 04:00 pm</td>
<td><strong>SESSION 8 • INDUSTRY CORNER</strong></td>
</tr>
<tr>
<td>04:00 pm</td>
<td><strong>Concluding remarks</strong></td>
</tr>
</tbody>
</table>
October 22 & 23, 2020, Paris

SCIENTIFIC PROGRAM

International Think Tank

FACULTY 2020

BAUMERT Thomas
BEDOSSA Pierre
CASTERA Laurent
DEVRIÈRE Jacques
DUFOUR Jean-François
FINKELSTEIN Dianne
FRIED Michael
FRIEDMAN Scott
GERBES Alexander
GONZALEZ Jean-Michel
JOHANSSON Lars
MAGRÉ Jocelyne
MANGELSドルF David
MARRA Fabio
MARCELLIN Patrick
MATHURIN Philippe
MILLER Veronica
MUKHOPADHYAY Bani
NEWSTONE Philip
PAIS Raluca
REGEV Arie
RODEN Michael
ROMEO Stefano
ROMERO-GÓMEZ Manuel
RINELLA Mary
SANYAL Arun
SERFATY Lawrence
SIDDIQUI Mohammad Shadab
STAELS Bart
TACKE Franck
TRAUNER Michael
TSOCHATZIS Emmanuel
VAN GAAL Luc

www.paris-nash.org
October 22 & 23, 2020, Paris

INSTITUT PASTEUR
28 Rue du Docteur Roux
75015 PARIS • FRANCE

Congress Secretariat
TAMING HEALTHCARE
24 rue des Bons Raisins
92150 Suresnes - France
+33 1 87 15 30 30

Contact:
contact@paris-nash.org
www.paris-nash.org